Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD).
For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

Tonix Pharmaceuticals is also enrolling participants in a Phase 3 trial for fibromyalgia.
For more information, please visit www.thereliefstudy.com or www.clinicaltrials.gov (NCT04172831).

News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study

December 16, 2019 • 3:15 PM EST

Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL

December 11, 2019 • 4:05 PM EST

Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

December 10, 2019 • 7:00 AM EST

Tonix Pharmaceuticals to Present at 12th Annual LD Micro Main Event

December 4, 2019 • 7:00 AM EST

Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

December 3, 2019 • 7:00 AM EST

Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD

November 26, 2019 • 4:05 PM EST

Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference

November 25, 2019 • 4:05 PM EST

Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

November 21, 2019 • 8:00 AM EST

Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder

November 20, 2019 • 4:05 PM EST

Tonix Pharmaceuticals Announces Closing of $9.0 Million Public Offering

November 20, 2019 • 7:00 AM EST

Show All

News / Press Releases : Press Releases